基于 HPLC-MS/MS 的利伐沙班与血液中因子 Xa 活性关系的研究。
Study on the Relationship between Rivaroxaban and Factor Xa Activity in Blood Based on HPLC-MS/MS.
机构信息
Department of Pharmacy, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
Department of Respiratory Medicine, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.
出版信息
Curr Drug Metab. 2021;22(14):1132-1138. doi: 10.2174/1389200222666211126093627.
OBJECTIVE
The aim of the study was to investigate a high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) method for the determination of rivaroxaban and evaluate the correlation between plasma concentration and anti-Xa activity in patients using oral rivaroxaban.
METHODS
In this study, the plasma concentration of rivaroxaban and anti-Xa factor activities was determined in 125 patients, and the relationship between the two variables was analysed by SPSS 21.0 software.
RESULTS
The results showed that the plasma concentrations of oral rivaroxaban patients were significantly correlated with the activity of the anti-Xa factor (Spearman's r = 0.990, P < 0.05).
CONCLUSION
The plasma concentrations of rivaroxaban are a potentially useful monitoring indicator to assess the patient's bleeding risk if testing for plasma anti-Xa activity is not available.
目的
本研究旨在建立一种高效液相色谱-串联质谱法（HPLC-MS/MS）测定口服利伐沙班患者血浆浓度，并评估其与抗 Xa 因子活性的相关性。
方法
本研究中，采用 HPLC-MS/MS 法测定了 125 例口服利伐沙班患者的血浆浓度，并采用 SPSS 21.0 软件分析了两种变量之间的关系。
结果
结果表明，口服利伐沙班患者的血浆浓度与抗 Xa 因子活性呈显著正相关（Spearman's r = 0.990，P < 0.05）。
结论
如果无法检测血浆抗 Xa 活性，利伐沙班的血浆浓度是评估患者出血风险的一种潜在有用的监测指标。
Zotero 插件